title: Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
authors.affiliation: Department of Internal Medicine, Section of Endocrinology and Metabolism, University of Siena, Sienna, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Pacini
authors.forename: M G
authors.initials: MG
authors.lastname: Castagna
authors.forename: L
authors.initials: L
authors.lastname: Brilli
authors.forename: G
authors.initials: G
authors.lastname: Pentheroudakis
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D018276:Carcinoma, Medullary / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy; D002291:Carcinoma, Papillary / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000628:therapy; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D065646:Thyroid Carcinoma, Anaplastic; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D013965:Thyroidectomy; D013974:Thyroxine / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D047428:Protein Kinase Inhibitors; D019275:Radiopharmaceuticals; D013974:Thyroxine